Company profile
Golden Developing Solutions, Inc.
OTC: DVLP · Healthcare · Drug Manufacturers - Specialty & Generic
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ 9GM —SS 38
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, return on assets · ↓ filing timeliness, disclosure history
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.4M
Employees
53
as of 2026-08-29
Market cap
$14.1k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02021
Net income-$1.4M-$1.4M2022
Operating income-$646.5k-$646.5k2022
Total assets$8.7M$8.7M2022
Liabilities$6.7M$6.7M2022
Equity$2.0M$2.0M2022
Revenue trend
FY2019 – FY2021 · USD
FY19
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Golden Developing Solutions, Inc.’s revenue?
Golden Developing Solutions, Inc. booked $0 in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Stem Cell Authority, Ltd.——ARYx Therapeutics, Inc.——VioQuest Pharmaceuticals, Inc.——CNBX Pharmaceuticals Inc.18DVaxxinity, Inc.——Thunder Energies Corporation——Neighbors
Broward →Key facts
CEOStavros A. Triant
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersFort Lauderdale, FL
ExchangeOTC: DVLP
Employees53
IPO date2016-09-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.